• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

    14.09 +2.05 (+17.03%)
    Streaming Delayed Price Updated: 3:49 PM EDT, Sep 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 469,002
    Open 13.60
    Bid (Size) 14.09 (600)
    Ask (Size) 14.13 (100)
    Prev. Close 12.04
    Today's Range 13.51 - 14.23
    52wk Range 9.770 - 18.30
    Shares Outstanding 871,256,270
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗
    HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The... 
    Via MarketBeat
    News headline image
    HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
    From HUTCHMED (China) Limited
    Via GlobeNewswire

    Performance

    YTD
    +3.2%
    +3.2%
    1 Month
    +22.0%
    +22.0%
    3 Month
    +24.6%
    +24.6%
    6 Month
    +3.3%
    +3.3%
    1 Year
    -8.0%
    -8.0%

    More News

    Read More
    News headline image
    HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED H1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    HUTCHMED Reports 2026 Interim Results
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED to Announce 2026 Half-Year Financial Results
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    Intended Retirement of Independent Non-executive Director and changes of composition of board committees
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Reports 2025 Full Year Results and Business Updates
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED to Announce 2025 Final Results
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    News headline image
    HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire

    Frequently Asked Questions

    Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?
    Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.
    What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?
    HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?
    The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market
    What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
    The current price of HUTCHMED (China) Limited - American Depositary Shares is 14.09
    When was HUTCHMED (China) Limited - American Depositary Shares last traded?
    The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 09/03/26 03:49 PM ET
    What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
    The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 12.28B
    How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
    HUTCHMED (China) Limited - American Depositary Shares has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.